Hot High Tech Stocks To Buy Right Now

The Dow Jones today jumped 57 points in pre-market trading after Facebook Inc. (Nasdaq: FB) posted better-than-expected earnings. Facebook beat revenue estimates by 4% and announced that it had increased its workforce by 48%. Much of the market expected Facebook to report losses on the heels of the multiple scandals that plagued the company throughout the first quarter.

With earnings season in full swing, there’s no better time to adopt a new trading strategy. Money Morning Quantitative Specialist Chris Johnson argues that the markets are at a tipping point. And with just a few smart plays in today’s classic “stock-picker’s market”… you can pull in triple-digit gains with just a small investment. Read those picks, right here.

Here are the numbers from Wednesday for the Dow, S&P 500, and Nasdaq:

Index Previous Close Point Change Percentage Change
Dow Jones 24,083.83 59.70 0.25%
Nasdaq 7,003.74 -3.61 -0.05
S&P 500 2,639.40 4.84 0.18%

Now here’s a closer look at today’s Money Morning insight, the most important market events, and stocks to watch.

Hot High Tech Stocks To Buy Right Now: Prothena Corporation plc(PRTA)

Advisors’ Opinion:

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Prothena Corporation plc (NASDAQ: PRTA) shares dipped 69 percent to $11.48 after a disappointing update relating to the company's treatment for AL amyloidosis. Prothena, a clinical-stage biopharmaceutical company that focuses on therapies in the neuroscience and orphan categories, said a Phase 2b study of its therapy called NEOD001 failed to achieve its primary or secondary endpoints. Prothena's Phase 2b study explored its NEOD001 therapy versus a placebo in previously-treated patients with AL amyloidosis and persistent cardiac dysfunction.
    Gridsum Holding Inc. (NASDAQ: GSUM) fell 44.3 percent to $4.06. Gridsum reported suspension of audit report on financial statements.
    Flotek Industries, Inc. (NYSE: FTK) shares declined 34.1 percent to $4.16 as the company issued weak revenue forecast for the first quarter.
    Akorn, Inc. (NASDAQ: AKRX) dropped 32.3 percent to $13.35 after Fresenius terminated its merger deal with Akorn.
    Chicago Bridge & Iron Company N.V. (NYSE: CBI) fell 31.2 percent to $13.44. Subsea 7 made an unsolicited bid to buy McDermott for $7 per share. However, the acquisition offer is contingent on McDermot terminating its pending merger with Chicago Bridge & Iron.
    Controladora Vuela Compañía de Aviación, S.A.B. de C.V. (NYSE: VLRS) dropped 18 percent to $5.76. Controladora Vuela recently reported first-quarter results that showed a loss for the quarter. Imperial Capital downgraded Controladora Vuela Compania de Aviacion from Outperform to In-Line.
    Atossa Genetics Inc. (NASDAQ: ATOS) fell 18.2 percent to $2.8797 after declining 19.35 percent on Friday.
    Alcoa Corporation (NYSE: AA) fell 12.3 percent to $52.63.
    Luby's, Inc. (NYSE: LUB) shares declined 10.3 percent to $2.448 following Q2 results.
    Aceto Corporation (NASDAQ: ACET) shares tumbled 10 percent to $2.26.
    Pier 1 Imports, Inc. (NYSE: PIR) dipped 9.7 percent

  • [By Max Byerly]

    Royal Bank of Canada reduced its stake in Prothena Co. PLC (NASDAQ:PRTA) by 40.0% during the first quarter, Holdings Channel reports. The fund owned 7,337 shares of the biotechnology company’s stock after selling 4,888 shares during the period. Royal Bank of Canada’s holdings in Prothena were worth $269,000 as of its most recent SEC filing.

  • [By Chris Lange]

    Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.

  • [By Cory Renauer]

    April’s been a month of biotech bloodbaths. In a 15-day span, Incyte Corporation (NASDAQ:INCY), Prothena Corporation PLC (NASDAQ:PRTA), and Celldex Therapeutics Inc. (NASDAQ:CLDX) have all reported clinical trial failures that have hammered their stock prices.

  • [By Lisa Levin]

    Prothena Corporation plc (NASDAQ: PRTA) shares dropped 68 percent to $11.79 after a disappointing update relating to the company's treatment for AL amyloidosis. Prothena, a clinical-stage biopharmaceutical company that focuses on therapies in the neuroscience and orphan categories, said a Phase 2b study of its therapy called NEOD001 failed to achieve its primary or secondary endpoints. Prothena's Phase 2b study explored its NEOD001 therapy versus a placebo in previously-treated patients with AL amyloidosis and persistent cardiac dysfunction. Unfortunately, there were no statistically significant difference between the two treatment groups.

  • [By Lisa Levin]

    Prothena Corporation plc (NASDAQ: PRTA) shares dropped 69 percent to $11.585 after a disappointing update relating to the company's treatment for AL amyloidosis. Prothena, a clinical-stage biopharmaceutical company that focuses on therapies in the neuroscience and orphan categories, said a Phase 2b study of its therapy called NEOD001 failed to achieve its primary or secondary endpoints. Prothena's Phase 2b study explored its NEOD001 therapy versus a placebo in previously-treated patients with AL amyloidosis and persistent cardiac dysfunction. Unfortunately, there were no statistically significant difference between the two treatment groups.

Hot High Tech Stocks To Buy Right Now: BlackLine, Inc. (BL)

Advisors’ Opinion:

  • [By Motley Fool Staff]

    The period-end close is a time-consuming and frustrating process that accountants in nearly every business have to deal with on a regular basis. BlackLine (NASDAQ:BL) is a software-as-a-service provider that brings order to this chaotic affair through automation. Businesses everywhere have been flocking to the service in an effort to bring their accounting process into the 21st century.

  • [By Brian Feroldi]

    There’s also a ton of room for niche applications for these businesses. One of the companies that we’ve touched on a few weeks ago when I was on the show was BlackLine (NASDAQ:BL). They have targeted this niche of real-time accounting software, which is something that not many other companies are going after. So, there is plenty of room, I think, for smaller players that take a more niche focus to succeed.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on BlackLine (BL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Keith Speights, Sean Williams, and Brian Feroldi]

    We asked three Motley Fool contributors to identify which small-cap stocks they like right now. They picked cloud-based software provider Blackline (NASDAQ:BL), up-and-coming biotech Supernus Pharmaceuticals (NASDAQ:SUPN), and cannabis distributor Origin House (NASDAQOTH:ORHOF). Here’s why these three small-cap stocks especially stand out.

Hot High Tech Stocks To Buy Right Now: Timken Steel Corporation(TMST)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Timkensteel (TMST)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    Timkensteel (NYSE: TMST) and APERAM/SH N Y REGISTRY SH (OTCMKTS:APEMY) are both basic materials companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability and earnings.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on TimkenSteel (TMST)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Timkensteel (TMST)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Leave a Reply

Your email address will not be published. Required fields are marked *